Zobrazeno 1 - 10
of 73
pro vyhledávání: '"Kosmidis, Paraskevas"'
Autor:
Nicolatou-Galitis, Ourania, Psyrri, Amanda, Tsoukalas, Nikolaos, Galitis, Evangelos, Linardou, Helena, Galiti, Dimitra, Athansiadis, Ilias, Kalapanida, Despoina, Razis, Evangelia, Katirtzoglou, Nikolaos, Kentepozidis, Nikolaos, Kosmidis, Paraskevas, Stavridi, Flora, Kyrodimos, Efthimios, Daliani, Danai, Tsironis, George, Mountzios, Giannis, Karageorgopoulou, Sofia, Gouveris, Panagiotis, Syrigos, Konstantinos
Publikováno v:
Oral; Mar2023, Vol. 3 Issue 1, p123-133, 11p
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Özdoğan, Mustafa, Papadopoulou, Eirini, Tsoulos, Nikolaos, Tsantikidi, Aikaterini, Vasiliki-Metaxa Mariatou, Tsaousis, Georgios, Kapeni, Evgenia, Bourkoula, Evgenia, Fotiou, Dimitrios, Kapetsis, Georgios, Boukovinas, Ioannis, Touroutoglou, Nikolaos, Fassas, Athanasios, Adamidis, Achilleas, Kosmidis, Paraskevas, Trafalis, Dimitrios, Galani, Eleni, Lypas, George, Orhan, Bülent, Sualp Tansan, Özatlı, Tahsin, Onder Kırca, Çakır, Okan, Nasioulas, George
Additional file 1: Table S1. Title: Genomic Regions and fusions analyzed with the 24 and 50 gene panels. Additional file 2: Table S2. Title: Gene alterations detected by the 161 gene panel. Description: The frequency of the different mutation types (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::046c4e863d2d5d6e1474f1e06be431f7
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Briassoulis, E. Ch, Samantas, E., Kalofonos, H. P., Skarlos, Dimosthenis V., Makatsoris, T., Christodoulou, C., Fountzilas, George, Bamias, A. T., Dimopoulos, M. A., Kosmidis, Paraskevas A., Pavlidis, Nicholas
Publikováno v:
Cancer chemotherapy and pharmacology
AIM: The irinotecan-cisplatin combination has emerged as a new standard for the treatment of advanced-stage small-cell lung cancer (AS-SCLC). To move forward we developed a 3-day regimen of cisplatin, etoposide and irinotecan. METHODS: Successive coh
Autor:
Aravantinos, Gerasimos, Bafaloukos, Dimitrios, Fountzilas, George, Christodoulou, C., Papadimitriou, C., Pavlidis, Nicholas, Kalofonos, H. P., Gogas, H., Kosmidis, Paraskevas A., Dimopoulos, M. A.
Publikováno v:
Annals of Oncology
Background: This multicenter, prospective phase II study evaluated the safety and efficacy of the combination of docetaxel and vinorelbine in patients with platinum-resistant, paclitaxel-pretreated recurrent ovarian cancer. Patients and methods: Trea
Autor:
Fountzilas, George, Papadimitriou, C., Dafni, U., Bafaloukos, Dimitrios, Skarlos, Dimosthenis V., Moulopoulos, L. A., Razi, E. D., Kalofonos, H. P., Aravantinos, Gerasimos, Briassoulis, E. Ch, Papakostas, P., Abela, K., Gogas, H., Kosmidis, Paraskevas A., Pavlidis, Nicholas, Dimopoulos, M. A.
Publikováno v:
Scopus-Elsevier
Journal of Clinical Oncology
Journal of Clinical Oncology
PURPOSE: To compare the efficacy of two different schedules of epirubicin and paclitaxel, as first-line chemotherapy, in patients with advanced breast cancer (ABC). PATIENTS AND METHODS: From October 1997 until May 1999, 183 eligible patients with AB
Autor:
Razi, E. D., Dimopoulos, M. A., Bafaloukos, Dimitrios, Papadimitriou, C., Kalogera-Fountzila, Anna, Kalofonos, H. P., Briassoulis, E. Ch, Samantas, E., Keramopoulos, A., Pavlidis, Nicholas, Kosmidis, Paraskevas A., Fountzilas, George
Publikováno v:
Cancer investigation
The purpose of this study was to evaluate the activity and toxicity profile of dose-dense sequential chemotherapy with epirubicin (EPI) and paclitaxel in advanced breast cancer (ABC). From January to September 1997, 41 patients with recurrent or meta
Autor:
Kosmidis, Paraskevas A., Mylonakis, N., Skarlos, Dimosthenis V., Samantas, E., Dimopoulos, M. A., Papadimitriou, C., Kalofonos, H. P., Pavlidis, Nicholas, Nikolaides, C., Papaconstantinou, C., Fountzilas, George
Publikováno v:
Annals of Oncology
Purpose: The combination of paclitaxel and carboplatin has become a widely used regimen in NSCLC due to phase II reports of moderate toxicity, reasonable activity and easy outpatient administration. Purpose of our present prospective study was to eva
Autor:
Fountzilas, George, Dimopoulos, M. A., Papadimitriou, C., Kalogera-Fountzila, Anna, Aravantinos, Gerasimos, Bafaloukos, Dimitrios, Athanasiades, A., Nikolaides, C., Keramopoulos, A., Pavlidis, Nicholas, Kosmidis, Paraskevas A., Skarlos, Dimosthenis V.
Publikováno v:
Annals of Oncology
Summary Purpose To evaluate the activity and toxicity of the combination of paclitaxel given by three-hour infusion, and carboplatin as first-line chemotherapy in patients with advanced breast cancer (ABC). Background Paclitaxel is an active agent in